
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
Novo Nordisk has invested $130 million in new diabetes laboratories as the company looks to focus more strongly on the …

A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …

An FDA panel has voted 14-1 to allow a form of Novo Nordisk’s type 2 diabetes treatment Victoza to help …

Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …

Development of Evotec and Hyperion Therapeutic’s diabetes drug DiaPep277 has been terminated following ‘serious misconduct’ in one of its trials. …

A restructuring of Novo Nordisk will see it completely drop its inflammatory disorders activities in favour of concentrating on its …

AstraZeneca and Japanese firm Mitsubishi Tanabe Pharma Corporation (MTPC) have signed a new three-year research deal in the area of …

Sanofi could pay out as much as $925 million for global rights to the world’s only approved inhaled insulin just …

The NHS spent more than £2.2 million on average every day over the last financial year on diabetes medicines, according …

Novartis eye care division Alcon has struck a deal with Google to develop a ‘smart’ contact lens designed to help …

NHS Scotland has spent around £230 million on diabetes and obesity drugs in the past three years, according to data …

The FDA has approved the first ‘ultra-rapid-acting’ mealtime insulin therapy available in the US, to improve glycemic control in both …

In final guidance NICE has recommended Janssen’s Invokana as a treatment to help lower blood sugar levels in people with …

Sanofi and Medtronic have announced a new tie-up that will see both firms develop new products in the increasingly competitive …